Results for the substance nirsevimab

Nirsevimab is a monoclonal antibody used to prevent severe respiratory syncytial virus (RSV) infections in infants and young children. This medication is particularly indicated for those at high risk of severe complications, such as premature infants or those with pre-existing lung or heart conditions.

Nirsevimab is administered via intramuscular injection, usually before the RSV season. It provides passive protection by neutralizing the virus and preventing its replication in the body.

Side effects are rare but may include injection site reactions, fever, or skin irritation. It is important that the medication is administered under the supervision of a specialist physician.

Nirsevimab represents an important option for reducing hospitalizations and complications associated with RSV, contributing to the protection of the most vulnerable patients.